Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Peg-IFNα-2a

Recombinant protein · developed by Arbutus Biopharma

Phase 2 Most advanced trial (none active)
ABUS Developer
1 Registered trials

What is Peg-IFNα-2a?

Peg-IFNα-2a is a pegylated recombinant interferon alpha 2a that binds interferon alpha receptors to activate antiviral and immune responses. It is studied in chronic hepatitis B infection.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
pegylated interferon alpha 2a
Drug type
Recombinant protein
Therapy area
Infectious disease
Developer
Arbutus Biopharma Corporation (ABUS)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04980482 Phase 2 Chronic Hepatitis b Completed ABUS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Chronic Hepatitis b

More from Arbutus Biopharma

AB-836 Phase 1 ARB-001467 Phase 2 Imdusiran Phase 2 PRO-040201 Phase 1 TKM-100201 Phase 1 TKM-100802 Phase 1 TKM-PLK1 Phase 1/2

Follow ABUS, the company behind Peg-IFNα-2a

See ABUS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ABUS catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.